From Surf Wiki (app.surf) — the open knowledge base

Eccrine carcinoma

Field	Value
name	Eccrine carcinoma
synonyms	Syringoid carcinoma
image	SkinTumors-P8110577.JPG
caption	Eccrine carcinoma, alveolar type
field	dermatology

Eccrine carcinoma is a rare skin condition characterized by a plaque or nodule on the scalp, trunk, or extremities. It originates from the eccrine sweat glands of the skin, accounting for less than 0.01% of diagnosed cutaneous malignancies. Eccrine carcinoma tumors are locally aggressive, with a high rate of recurrence. Lack of reliable immunohistochemical markers and similarity to other common tumors has made identification of eccrine carcinoma difficult.

Most eccrine carcinomas which have not spread can be cured by wide local excision. However, metastatic disease carries a poor prognosis.

Symptoms

Eccrine carcinoma results in brown, bluish, erythematous skin lesions across the body. Common regions where lesions are found are in the lower extremities (35%), head and neck (24%), and upper extremities (14%).

Complications

Metastases and/or antagonistic side effects can occur after surgical excision of tumors.

Types

Eccrine carcinomas include porocarcinoma, hidradenocarcinoma, malignant spiradenoma carcinoma, malignant cylindroma, syringoid eccrine carcinoma, microcystic adnexal carcinoma, mucinous carcinoma, adenoid cystic carcinoma, and ductal papillary adenocarcinoma. Other tumors not classified include eccrine ductal carcinoma, basaloid eccrine carcinoma, clear cell eccrine carcinoma and non-specified sweat gland carcinomas.

Causes

There is no research yet as to what causes Eccrine carcinoma.

Diagnosis

A skin biopsy is the most common test used to diagnose eccrine carcinoma. The biopsy will detect growth of new or abnormal tissue. Another test that can be performed is using immunohistochemistry, but it is inconsistent. Markers used to detect eccrine carcinoma consist of carcinoembryonic antigen, progesterone receptors, estrogen receptors, epithelial membrane antigen, pancytokeratins, and cytokeratin 7.

Treatment

Wide surgical excision is the mainstay of treatment. Chemotherapy and radiation therapy have been used in metastatic disease.

Prognosis

In the absence of metastasis, local excision is curative in 70–80% of cases. Metastatic eccrine carcinoma has a relative mortality rate of 65% (with local lymph node involvement alone) to 80% (with distant metastases), and the 10-year overall survival rate is 9%.

Frequency

Eccrine carcinoma accounts for 0.005-0.01% of diagnosed cutaneous malignancies.

References

(2006). "Andrews' Diseases of the Skin: Clinical Dermatology". Saunders Elsevier.
(2020). "Cancer, An Overview of Eccrine Carcinoma". StatPearls Publishing.
(2018). "Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma". Case Reports in Oncological Medicine.
(2013-02-04). "Eccrine carcinoma: a rare cutaneous neoplasm". Diagnostic Pathology.
(1987–2004). "Eccrine sweat gland carcinoma: an histologic and immunohistochemical study of 32 cases*". Journal of Cutaneous Pathology.
(2002–2010). "Syringoid Eccrine Carcinoma". The American Journal of Dermatopathology.
(1991–2005). "Syringoid eccrine carcinoma". Journal of the American Academy of Dermatology.
(2011-06-04). "Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases". Journal of Clinical Pathology.
(2017). "Porocarcinoma: A systematic review of literature with a single case report". International Journal of Surgery Case Reports.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

epidermal-nevi,-neoplasms,-and-cysts

Want to explore this topic further?

Ask Mako anything about Eccrine carcinoma — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report